EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
Publishing timestamp: 2024-04-12 12:00:50
Summary
European Union drug regulators found no evidence linking popular weight loss and diabetes drugs like Wegovy and Ozempic to increased risk of suicidal thoughts and self-injury after conducting a nine-month investigation. The review included drugs from Novo Nordisk but not Eli Lilly's Zepbound and Mounjaro. The investigation confirmed the safety of GLP-1s, a class of treatments that mimic gut hormones to suppress appetite, despite initial concerns raised by Icelandic Medicines Agency.
Sentiment: NEUTRAL
Keywords: biotechnology, eli lilly and co, breaking news, business, health care industry, pharmaceuticals, biotech and pharmaceuticals, novo nordisk a/s, social issues, business news,